Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 1,001–1,079 of 1,079

1. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
   Sutani, A, Nagai, Y, Udagawa, K, Uchida, Y, Koyama, N, Murayama, Y, Tanaka, T, Miyazawa, H, Nagata, M, Kanazawa, M et al. · 2006 · British Journal of Cancer
2. Association of <i>KRAS</i> and <i>EGFR</i> mutations with survival in patients with advanced lung adenocarcinomas
   Johnson, Melissa L., Sima, Camelia S., Chaft, Jamie, Paik, Paul K., Pao, William, Kris, Mark G., Ladanyi, Marc, Riely, Gregory J. · 2013 · Cancer
3. Targeting EGFR ^L858R/T790M and EGFR ^{L858R/T790M/C797S} resistance mutations in NSCLC: Current developments in medicinal chemistry
   Lu, Xiaoyun, Yu, Lei, Zhang, Zhang, Ren, Xiaomei, Smaill, Jeff B., Ding, Ke · 2018 · Medicinal Research Reviews
4. Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
   Ségaliny, Aude I., Tellez-Gabriel, Marta, Heymann, Marie-Françoise, Heymann, Dominique · 2015 · Journal of Bone Oncology
5. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium
   Pacheco-Pinedo, Eugenia C., Durham, Amy C., Stewart, Kathleen M., Goss, Ashley M., Lu, Min Min, DeMayo, Francesco J., Morrisey, Edward E. · 2011 · Journal of Clinical Investigation
6. <i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
   Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro et al. · 2015 · Oncotarget
7. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
   Costa, Daniel B., Kobayashi, Susumu, Tenen, Daniel G., Huberman, Mark S. · 2007 · Lung Cancer
8. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
   Cortot, Alexis B., Jänne, Pasi A. · 2014 · European Respiratory Review
9. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
   Yamamoto, Chizuko, Basaki, Yuji, Kawahara, Akihiko, Nakashima, Kazutaka, Kage, Masayoshi, Izumi, Hiroto, Kohno, Kimitoshi, Uramoto, Hidetaka, Yasumoto, Kosei, Kuwano, Michihiko et al. · 2010 · Cancer Research
10. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C et al. · 2017 · British Journal of Cancer
11. <i>PIK3CA</i> mutation is an early event in the development of endometriosis‐associated ovarian clear cell adenocarcinoma
    Yamamoto, Sohei, Tsuda, Hitoshi, Takano, Masashi, Iwaya, Keichi, Tamai, Seiichi, Matsubara, Osamu · 2011 · The Journal of Pathology
12. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jänne, Pasi A., Johnson, Bruce E. · 2006 · Clinical Cancer Research
13. A catalogue of somatic NRF2 gain-of-function mutations in cancer
    Kerins, Michael John, Ooi, Aikseng · 2018 · Scientific Reports
14. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response
    Gow, Chien-Hung, Chien, Chun-Ru, Chang, Yih-Leong, Chiu, Yueh-Hsia, Kuo, Sung-Hsin, Shih, Jin-Yuan, Chang, Yeun-Chung, Yu, Chong-Jen, Yang, Chih-Hsin, Yang, Pan-Chyr · 2008 · Clinical Cancer Research
15. <i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer
    Konduri, Kartik, Gallant, Jean-Nicolas, Chae, Young Kwang, Giles, Francis J., Gitlitz, Barbara J., Gowen, Kyle, Ichihara, Eiki, Owonikoko, Taofeek K., Peddareddigari, Vijay, Ramalingam, Suresh S. et al. · 2016 · Cancer Discovery
16. A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib
    de La Motte Rouge, Thibault, Galluzzi, Lorenzo, Olaussen, Ken A., Zermati, Yael, Tasdemir, Ezgi, Robert, Thomas, Ripoche, Hugues, Lazar, Vladimir, Dessen, Philippe, Harper, Francis et al. · 2007 · Cancer Research
17. Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring <i>K-RAS</i> Mutations
    Konstantinidou, Georgia, Bey, Erik A., Rabellino, Andrea, Schuster, Katja, Maira, Michael S., Gazdar, Adi F., Amici, Augusto, Boothman, David A., Scaglioni, Pier Paolo · 2009 · Cancer Research
18. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor: A Meta-analysis
    Lee, June-Koo, Hahn, Seokyung, Kim, Dong-Wan, Suh, Koung Jin, Keam, Bhumsuk, Kim, Tae Min, Lee, Se-Hoon, Heo, Dae Seog · 2014 · JAMA
19. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
    Yoshikawa, S, Kukimoto-Niino, M, Parker, L, Handa, N, Terada, T, Fujimoto, T, Terazawa, Y, Wakiyama, M, Sato, M, Sano, S et al. · 2013 · Oncogene
20. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response
    Wong, Harvey, Choo, Edna F., Alicke, Bruno, Ding, Xiao, La, Hank, McNamara, Erin, Theil, Frank-Peter, Tibbitts, Jay, Friedman, Lori S., Hop, Cornelis E.C.A. et al. · 2012 · Clinical Cancer Research
21. Pooled Analysis of the Prognostic and Predictive Effects of <i>TP53</i> Comutation Status Combined With <i>KRAS</i> or <i>EGFR</i> Mutation in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
    Shepherd, Frances A., Lacas, Benjamin, Le Teuff, Gwénaël, Hainaut, Pierre, Jänne, Pasi A., Pignon, Jean-Pierre, Le Chevalier, Thierry, Seymour, Lesley, Douillard, Jean-Yves, Graziano, Stephen et al. · 2017 · Journal of Clinical Oncology
22. EGF816 Exerts Anticancer Effects in Non–Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor
    Jia, Yong, Juarez, Jose, Li, Jie, Manuia, Mari, Niederst, Matthew J., Tompkins, Celin, Timple, Noelito, Vaillancourt, Mei-Ting, Pferdekamper, AnneMarie Culazzo, Lockerman, Elizabeth L. et al. · 2016 · Cancer Research
23. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
    Yen, Hsin-Yung, Liu, Ying-Chih, Chen, Nai-Yu, Tsai, Chia-Feng, Wang, Yi-Ting, Chen, Yu-Ju, Hsu, Tsui-Ling, Yang, Pan-Chyr, Wong, Chi-Huey · 2015 · Proceedings of the National Academy of Sciences
24. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
    Cho, Jeonghee, Chen, Liang, Sangji, Naveen, Okabe, Takafumi, Yonesaka, Kimio, Francis, Joshua M., Flavin, Richard J., Johnson, William, Kwon, Jihyun, Yu, Soyoung et al. · 2013 · Cancer Research
25. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
    Keam, Bhumsuk, Kim, Dong-Wan, Park, Jin Hyun, Lee, Jeong-Ok, Kim, Tae Min, Lee, Se-Hoon, Chung, Doo Hyun, Heo, Dae Seog · 2014 · International Journal of Clinical Oncology
26. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
27. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer
    Tan, Chee-Seng, Cho, Byoung-Chul, Soo, Ross A. · 2016 · Lung Cancer
28. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy
    Chen, Qian, Xu, Ligeng, Chen, Jiawen, Yang, Zhijuan, Liang, Chao, Yang, Yu, Liu, Zhuang · 2017 · Biomaterials
29. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
    Gong, Ke, Guo, Gao, Gerber, David E., Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D., Hatanpaa, Kimmo J., Kernstine, Kemp, Cai, Ling et al. · 2018 · Journal of Clinical Investigation
30. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
    Neel, Dana S., Bivona, Trever G. · 2017 · npj Precision Oncology
31. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
    Xu, Jianlin, Jin, Bo, Chu, Tianqing, Dong, Xue, Yang, Haitang, Zhang, Yanwei, Wu, Dan, Lou, Yuqing, Zhang, Xueyan, Wang, Huiming et al. · 2016 · Lung Cancer
32. Common <i>EGFR</i> -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors
    Reguart, Noemi, Remon, Jordi · 2015 · Future Oncology
33. Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
    Arasada, Rajeswara Rao, Shilo, Konstantin, Yamada, Tadaaki, Zhang, Jianying, Yano, Seiji, Ghanem, Rashelle, Wang, Walter, Takeuchi, Shinji, Fukuda, Koji, Katakami, Nobuyuki et al. · 2018 · Nature Communications
34. Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
    Lee, Ho-June, Schaefer, Gabriele, Heffron, Timothy P., Shao, Lily, Ye, Xiaofen, Sideris, Steve, Malek, Shiva, Chan, Emily, Merchant, Mark, La, Hank et al. · 2013 · Cancer Discovery
35. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
    Hasako, Shinichi, Terasaka, Miki, Abe, Naomi, Uno, Takao, Ohsawa, Hirokazu, Hashimoto, Akihiro, Fujita, Ryoto, Tanaka, Kenji, Okayama, Takashige, Wadhwa, Renu et al. · 2018 · Molecular Cancer Therapeutics
36. AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
    Xu, Xiao, Mao, Long, Xu, Wanhong, Tang, Wei, Zhang, Xiaoying, Xi, Biao, Xu, Rongda, Fang, Xin, Liu, Jia, Fang, Ce et al. · 2016 · Molecular Cancer Therapeutics
37. PROTAC therapy as a new targeted therapy for lung cancer
    Li, Jennifer W., Zheng, Guangrong, Kaye, Frederic J., Wu, Lizi · 2023 · Molecular Therapy
38. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
    Yuza, Yuki, Glatt, Karen A., Jiang, Jingrui, Greulich, Heidi, Minami, Yuko, Woo, Michele S., Shimamura, Takeshi, Shapiro, Geoffrey I., Lee, Jeffrey C., Ji, Hongbin et al. · 2007 · Cancer Biology &amp; Therapy
39. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases
    Mak, K. S., Gainor, J. F., Niemierko, A., Oh, K. S., Willers, H., Choi, N. C., Loeffler, J. S., Sequist, L. V., Shaw, A. T., Shih, H. A. · 2015 · Neuro-Oncology
40. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
    Gong, Meiling, Li, Yan, Ye, Xiaoping, Zhang, Linlin, Wang, Zhifang, Xu, Xiaowen, Shen, Yejing, Zheng, Cuixia · 2020 · Cell Communication and Signaling
41. Sample features associated with success rates in population-based EGFR mutation testing
    Shiau, Carolyn J., Babwah, Jesse P., da Cunha Santos, Gilda, Sykes, Jenna R., Boerner, Scott L., Geddie, William R., Leighl, Natasha B., Wei, Cuihong, Kamel-Reid, Suzanne, Hwang, David M. et al. · 2014 · Journal of Thoracic Oncology
42. NSCLC and HER2: between lights and shadows
    Ricciardi, Giuseppina Rosaria Rita, Russo, Alessandro, Franchina, Tindara, Ferraro, Giuseppa, Zanghì, Mariangela, Picone, Antonio, Scimone, Antonino, Adamo, Vincenzo · 2014 · Journal of Thoracic Oncology
43. Targeting Ras in myeloid leukemias
    Braun, Benjamin S., Shannon, Kevin · 2008 · Clinical Cancer Research
44. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
    Kuiper, J L, Hashemi, S M S, Thunnissen, E, Snijders, P J F, Grünberg, K, Bloemena, E, Sie, D, Postmus, P E, Heideman, D A M, Smit, E F · 2016 · British Journal of Cancer
45. Evaluation of Alternative <i>In Vivo</i> Drug Screening Methodology: A Single Mouse Analysis
    Murphy, Brendan, Yin, Han, Maris, John M., Kolb, E. Anders, Gorlick, Richard, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Kurmasheva, Raushan T., Dvorchik, Igor et al. · 2016 · Cancer Research
46. A genetic interaction analysis identifies cancer drivers that modify EGFR dependency
    Liao, Sida, Davoli, Teresa, Leng, Yumei, Li, Mamie Z., Xu, Qikai, Elledge, Stephen J. · 2017 · Genes &amp; Development
47. Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
    Chung, Kuei-Pin, Wu, Shang-Gin, Wu, Jenn-Yu, Yang, James Chih-Hsin, Yu, Chong-Jen, Wei, Pin-Fei, Shih, Jin-Yuan, Yang, Pan-Chyr · 2012 · Clinical Cancer Research
48. Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway
    Kometani, Takuro, Yoshino, Ichiro, Miura, Naoko, Okazaki, Hiroshi, Ohba, Taro, Takenaka, Tomoyoshi, Shoji, Fumihiro, Yano, Tokujiro, Maehara, Yoshihiko · 2009 · Cancer Letters
49. Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)
    Heppner, David E., Wittlinger, Florian, Beyett, Tyler S., Shaurova, Tatiana, Urul, Daniel A., Buckley, Brian, Pham, Calvin D., Schaeffner, Ilse K., Yang, Bo, Ogboo, Blessing C. et al. · 2022 · ACS Medicinal Chemistry Letters
50. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
    Choi, Yun Jung, Rho, Jin Kyung, Jeon, Byung-suk, Choi, Su Jin, Park, Su Cheol, Lee, Seung Sook, Kim, Hye-Ryoun, Kim, Cheol Hyeon, Lee, Jae Cheol · 2010 · Cancer Chemotherapy and Pharmacology
51. NSCLC harboring EGFR exon‐20 insertions after the regulatory <scp>C</scp>‐helix of kinase domain responds poorly to known EGFR inhibitors
    Yang, Mengmeng, Xu, Xiaoxi, Cai, Jie, Ning, Jinying, Wery, Jean Pierre, Li, Qi‐Xiang · 2016 · International Journal of Cancer
52. AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo
    Xie, Hua, Lin, Liping, Tong, Linjiang, Jiang, Yong, Zheng, Mingyue, Chen, Zhuo, Jiang, Xiaoyan, Zhang, Xiaowei, Ren, Xiaowei, Qu, Wenchao et al. · 2011 · PLoS ONE
53. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
    Pilotto, Sara, Rossi, Antonio, Vavalà, Tiziana, Follador, Alessandro, Tiseo, Marcello, Galetta, Domenico, Morabito, Alessandro, Di Maio, Massimo, Martelli, Olga, Caffo, Orazio et al. · 2018 · Clinical Lung Cancer
54. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non–Small Cell Lung Cancers
    Momcilovic, Milica, McMickle, Robert, Abt, Evan, Seki, Atsuko, Simko, Sarah A., Magyar, Clara, Stout, David B., Fishbein, Michael C., Walser, Tonya C., Dubinett, Steven M. et al. · 2015 · Cancer Research
55. MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
    Smida, Michal, Fece de la Cruz, Ferran, Kerzendorfer, Claudia, Uras, Iris Z., Mair, Barbara, Mazouzi, Abdelghani, Suchankova, Tereza, Konopka, Tomasz, Katz, Amanda M., Paz, Keren et al. · 2016 · Nature Communications
56. Structural basis of mutant-selectivity and drug-resistance related to CO-1686
    Yan, Xiao-E, Zhu, Su-Jie, Liang, Ling, Zhao, Peng, Choi, Hwan Geun, Yun, Cai-Hong · 2017 · Oncotarget
57. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
    Lin, Yen-Ting, Liu, Yi-Nan, Wu, Shang-Gin, Yang, James Chih-Hsin, Shih, Jin-Yuan · 2017 · Clinical Lung Cancer
58. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
    Liffers, Katrin, Kolbe, Katarina, Westphal, Manfred, Lamszus, Katrin, Schulte, Alexander · 2016 · Targeted Oncology
59. EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
    Venugopalan, Abhilash, Lee, Min-Jung, Niu, Gang, Medina-Echeverz, José, Tomita, Yusuke, Lizak, Martin J., Cultraro, Constance M., Simpson, Robert Mark, Chen, Xiaoyuan, Trepel, Jane B. et al. · 2016 · Oncotarget
60. Identification of a new inhibitor of KRAS‐PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
    Leung, Elaine Lai‐Han, Luo, Lian Xiang, Li, Ying, Liu, Zhong‐Qiu, Li, Lan Lan, Shi, Dan Feng, Xie, Ying, Huang, Min, Lu, Lin Lin, Duan, Fu Gang et al. · 2019 · International Journal of Cancer
61. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer
    Yap, Timothy A., Macklin-Doherty, Aislinn, Popat, Sanjay · 2017 · European Journal of Cancer
62. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung
    Lee, Youngjoo, Han, Ji-Youn, Kim, Heung Tae, Yun, Tak, Lee, Geon Kook, Kim, Hyae Young, Lee, Jin Soo · 2013 · Journal of Neuro-Oncology
63. Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
    Hampton, Kaia K., Craven, Rolf J. · 2014 · Oncoscience
64. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels
    Iivanainen, Erika, Lauttia, Susanna, Zhang, Na, Tvorogov, Denis, Kulmala, Jarmo, Grenman, Reidar, Salven, Petri, Elenius, Klaus · 2009 · Microvascular Research
65. Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type<i>EGFR</i>or Resistant Mutations
    Wheler, Jennifer J., Tsimberidou, Apostolia M., Falchook, Gerald S., Zinner, Ralph G., Hong, David S., Fok, Jansina Y., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Kurzrock, Razelle · 2013 · Molecular Cancer Therapeutics
66. Cancerous perturbations within the ERK, PI3K/Akt, and Wnt/β-catenin signaling network constitutively activate inter-pathway positive feedback loops
    Padala, Rahul Rao, Karnawat, Rishabh, Viswanathan, Satish Bharathwaj, Thakkar, Abhishek Vijay, Das, Asim Bikas · 2017 · Molecular BioSystems
67. EGFR-specific tyrosine kinase inhibitor modifies NK cell-mediated antitumoral activity against ovarian cancer cells
    Mallmann-Gottschalk, Nina, Sax, Yvonne, Kimmig, Rainer, Lang, Stephan, Brandau, Sven · 2019 · International Journal of Molecular Sciences
68. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
    Cardona, Andrés F., on behalf of the CLICaP, Rojas, Leonardo, Wills, Beatriz, Arrieta, Oscar, Carranza, Hernán, Vargas, Carlos, Otero, Jorge, Corrales-Rodriguez, Luis, Martín, Claudio et al. · 2016 · Oncotarget
69. Dacomitinib in lung cancer: a &amp;ldquo;lost generation&amp;rdquo; EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou, Sai-Hong, Soo, Ross · 2015 · Drug Design, Development and Therapy
70. Inhibition of MEK1/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-driven cancer
    Vaishnavi, Aria, Scherzer, Michael T., Kinsey, Conan G., Parkman, Gennie L., Truong, Amanda, Ghazi, Phaedra, Schuman, Sophia, Battistone, Benjamin, Garrido-Laguna, Ignacio, McMahon, Martin · 2020 · Cell Reports
71. Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
    Paweletz, Cloud P., Heavey, Grace A., Kuang, Yanan, Durlacher, Emily, Kheoh, Thian, Chao, Richard C., Spira, Alexander I., Leventakos, Konstantinos, Johnson, Melissa L., Ou, Sai-Hong Ignatius et al. · 2023 · Clinical Cancer Research
72. Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer
    Mendes, Cindy, Serpa, Jacinta · 2019 · Antioxidants
73. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
    Liu, Xiaoke, Hong, Lingzhi, Nilsson, Monique, Hubert, Shawna Marie, Wu, Shuhong, Rinsurongkawong, Waree, Lewis, Jeffery, Spelman, Amy, Roth, Jack, Swisher, Steven et al. · 2020 · Lung Cancer
74. Integrative modeling of multi-platform genomic data under the framework of mediation analysis
    Huang, Yen‐Tsung · 2015 · Statistics in Medicine
75. Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
    Wheler, Jennifer, Falchook, Gerald, Tsimberidou, Apostolia M., Hong, David, Naing, Aung, Piha-Paul, Sarina, Chen, Su S., Heymach, John, Fu, Siqing, Stephen, Bettzy et al. · 2013 · Oncotarget
76. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
    Frega, Stefano, Lorenzi, Martina, Fassan, Matteo, Indraccolo, Stefano, Calabrese, Fiorella, Favaretto, Adolfo, Bonanno, Laura, Polo, Valentina, Zago, Giulia, Lunardi, Francesca et al. · 2017 · Oncotarget
77. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
    Oh, Hwanhee, Hwang, Inah, Jang, Ja-Young, Wu, Lingxiang, Cao, Dongqing, Yao, Jun, Ying, Haoqiang, Li, Jian Yi, Yao, Yu, Hu, Baoli et al. · 2021 · Cancer Research
78. Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation
    OIKAWA, TAKEFUMI, OHIRA, TATSUO, OTANI, KEISHI, HAGIWARA, MASARU, KONAKA, CHIMORI, IKEDA, NORIHIKO · 2015 · Molecular and Clinical Oncology
79. Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer
    Wang, Shuhang, An, Tongtong, Duan, Jianchun, Zhang, Lijian, Wu, Meina, Zhou, Qinghua, Chen, Jinfeng, Zhuo, Minglei, Yang, Lu, Wang, Yuyan et al. · 2013 · PLoS ONE